Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 12, 2023
Share
Universal Vision Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 1,061.53 million compared to TWD 911.45 million a year ago. Net income was TWD 266.18 million compared to TWD 206.36 million a year ago. Basic earnings per share from continuing operations was TWD 3.14 compared to TWD 2.44 a year ago. Diluted earnings per share from continuing operations was TWD 3.14 compared to TWD 2.43 a year ago.
For the nine months, sales was TWD 3,089.38 million compared to TWD 2,536.33 million a year ago. Net income was TWD 791.96 million compared to TWD 606.74 million a year ago. Basic earnings per share from continuing operations was TWD 9.35 compared to TWD 7.16 a year ago. Diluted earnings per share from continuing operations was TWD 9.33 compared to TWD 7.15 a year ago.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 
